4 Cannabis Stocks Log Momentum Gains Even As Congress Re-Criminalizes Some THC Products In Spending Bill

Four cannabis stocks—Tilray (TLRY), Cronos (CRON), Organigram (OGI), and SNDL (SNDL)—are demonstrating strong technical momentum, according to Benzinga Edge rankings, even as a new U.S. government funding bill includes a provision to re-criminalize many hemp-derived THC products. This legislative development, which could significantly disrupt the market, is poised to benefit U.S. multi-state operators by eliminating "gray-market" competition, while potentially hindering Canadian firms like Tilray that aimed to leverage hemp products for U.S. market entry.

Analysis

Four cannabis stocks—Tilray (TLRY), Cronos (CRON), Organigram (OGI), and SNDL (SNDL)—are exhibiting strong technical momentum, as indicated by Benzinga Edge's "Green" rankings, despite significant regulatory uncertainty. This technical strength is notable given the mixed performance across various timeframes, with 6-month returns ranging from 20.39% (CRON) to 156.82% (TLRY), though year-to-date and one-year returns show more variability, including negative figures for TLRY (-22.60% YTD) and SNDL (-12.82% 1-year). Cronos Group (CRON) and SNDL registered pre-market gains of 3.63% and 2.35% respectively, while Tilray (TLRY) and Organigram (OGI) saw declines of 1.77% and 1.95%.

The primary headwind is a new provision in a government funding bill that effectively re-criminalizes many hemp-derived THC products, previously legalized under the 2018 Farm Bill. This legislative change is expected to significantly disrupt the market, potentially eliminating "gray-market" competition for U.S. multi-state operators. Conversely, it poses a substantial threat to Canadian firms like Tilray, which had strategically targeted the hemp-derived product segment for U.S. market entry.

The observed technical momentum appears to be largely disconnected from this adverse regulatory development, creating a complex investment landscape. While some stocks show strong medium to long-term price trends, such as TLRY and CRON, SNDL is noted for a weaker price trend across all timeframes despite a moderate growth ranking, highlighting idiosyncratic factors at play within the sector.

Key Decisions for Investors

• Investors should critically assess the impact of the re-criminalization of hemp-derived THC products, particularly on Canadian operators with U.S. market entry strategies like Tilray.
• Consider the divergence between strong technical momentum and potential fundamental headwinds from regulatory changes, evaluating individual company exposure and growth prospects.
• Monitor for shifts in market structure, as U.S. multi-state operators may benefit from reduced "gray-market" competition, potentially creating differentiated investment opportunities.